Emibetuzumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameEmibetuzumab
Drug Alias NameEmibetuzumabum依玛妥珠单抗Anti-c-MET-monoclonal-antibody-Eli-Lilly艾米妥组单抗cMET antibody - Eli Lilly +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksWikipedia